Publications by authors named "M Assayag"

Background: Cosmetic limb lengthening has been rapidly growing ever since the advent of the external fixators magnetic lengthening nails. Similar to all surgical procedures, cosmetic limb lengthening is not risk free. This paper presents a series of complications encountered and treated at a specialized limb lengthening and deformity correction center, along with an analysis of potential risk factors.

View Article and Find Full Text PDF

Purpose: Previous studies have shown that subtrochanteric femoral fractures treated with intramedullary nails might lead to varus-procurvatum malalignment. Similar results have been reported when using antegrade intramedullary lengthening nails (ILNs). The purpose of our study is to examine if antegrade telescoping intramedullary lengthening nails lead to varus-procurvatum malalignment of the proximal femur and what are possible predictors of that shift.

View Article and Find Full Text PDF

Purpose: The use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This report addresses the AL patient cohort treated to date within the phase Ia/Ib clinical trial (ClinicalTrials.

View Article and Find Full Text PDF

Background: In today's world, individuals receive much of their medical information from the Internet, including social media platforms such as the increasingly popular TikTok, a video-sharing site. This study's purpose was to better understand the content popular online regarding clubfoot deformity.

Methods: The 50 most viewed, English language videos on TikTok with the tags #clubfootjourney, #talipes, #clubfootcast, #clubfoottreatment, and #clubfoot were identified and independently evaluated by 2 separate reviewers for creator demographics, video type, and prominent themes.

View Article and Find Full Text PDF

Introduction: Treatment for relapsed/refractory AL amyloidosis (AL) is an unmet need. The safety and efficacy of belantamab mafodotin (BLM) in multiple myeloma are known, whereas in AL data are limited.

Methods: We report a multi-center cohort of AL patients receiving BLM, and review all previous data on BLM therapy in AL.

View Article and Find Full Text PDF